
Recapturing Disease Response: A Phase 2 Study of Carfilzomib 56 mg/m 2 in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Carfilzomib 27 mg/m 2
Barley, Kevin, Sanchez, Larysa, Cho, Hearn J., Parekh, Samir, Madduri, Deepu, Richter, Joshua, Isola, Luis, Goldstein, Talia, Dhadwal, Amishi, Zarychta, Katarzyna, Sanchez, Gillian Morgan, Catamero, DJournal:
American Journal of Hematology
DOI:
10.1002/ajh.25695
Date:
December, 2019
Fichier:
PDF, 287 KB
2019